Experts believe the B.1.617 variant is driving the huge wave in infections seen across India in recent weeks. The country now makes up 50% of Covid-19 cases and 30% of deaths from the virus globally, according to the World Health Organization (WHO).
The WHO designated B.1.617 and its sublineages as a “variant of concern” on May 10. That classification means a variant may be more transmissible or cause more severe disease, fail to respond to treatment, evade immune response or fail to be diagnosed by standard tests.
Here’s what you need to know.
The WHO said B.1.617 showed signs of potentially being more transmissible than some other strains of the virus, but cautioned that more research was required. Although Indian officials say the variant is driving the country’s crippling second wave, the WHO has said several other contributing factors — such as mass gatherings — have likely also contributed to the spread there.
The United Kingdom, which has world-class virus sequencing capabilities, warned that B.1.617.2 — a subtype of the variant first found in India — would likely overtake others, such as the highly transmissible B.1.1.7 first found in the UK last year, to become the most dominant variant of the virus in the country.
“The thing which has changed is the very clear view now that everyone has looked at it, that [B.1.617.2] is more transmissible than the B.1.1.7 and we expect, over time, this variant to overtake and come to dominate in the UK, in the way that B.1.1.7 took over and indeed other variants have taken over prior to that,” England’s chief medical officer Professor Chris Whitty said Friday.
As of now, there’s no evidence that B.1.617 is causing more severe illness.
Lab research into the efficacy of the Pfizer and Moderna vaccines against the variants first seen in India showed that the shots appear to protect against variants. The findings were reported in a pre-print paper on biorxiv.org on Sunday, which has not yet been peer-reviewed.
The new research involved serum samples collected from eight people who had recovered from Covid-19, six people fully vaccinated with the Pfizer vaccine and three people fully vaccinated with Moderna’s. The researchers analyzed in lab experiment how the serum samples neutralized lentiviruses — a type of retrovirus — equipped with the same mutations as the B.1.617 and B.1.618 coronavirus variants.
They found some decreases in neutralization, but overall, antibodies from people who had been vaccinated appeared to work “well above” the serum from people who had recovered from Covid-19 caused by earlier versions of the coronavirus.
More research is needed to determine just how effective the vaccines are against those variants in the real world, they said.
Their findings appear to confirm what researchers from Oxford University are seeing in early real-life data, which give “a degree of confidence” that vaccines work against the variants, UK heath secretary Matt Hancock told Sky News on Sunday.
He echoed other scientists who have been cautiously optimistic about the efficacy of vaccines. Sir John Bell, Oxford’s Emeritus Professor of Medicine, told Times Radio that early lab results suggest the B.1.617.2 variant “will be susceptible to the vaccine in the way that others are.”
While the variant is now the dominant strain in some parts of the UK, Hancock said “the people who are ending up in hospital are largely people who are eligible for the vaccine but have not taken the vaccine.”
The United Kingdom has reported the largest number of cases of the strain outside India, it said.
The outbreak there has already had an impact on global vaccine supply. India is a leading maker of vaccines but when cases started to spike, its government restricted the export of Covid-19 shots.
And the more the virus spreads, the more chances it has to mutate and create new variants that could eventually resist current vaccines, threatening to undermine other countries’ progress in containing the pandemic.
CNN’s Maggie Fox, Kara Fox, Ivana Kottasová, Robert Iddiols and Aditi Sangal contributed to this report.